Who makes VAX161 [STF2.HA5 H5N1]?

VAX161 [STF2.HA5 H5N1] is developed by VaxInnate Corporation.

What development phase is VAX161 [STF2.HA5 H5N1] in?

VAX161 [STF2.HA5 H5N1] is in Phase 1.

Last reviewed 2026-04-19 · How we verify

VAX161 [STF2.HA5 H5N1]

VaxInnate Corporation · Phase 1 active Biologic

At a glance

Generic name	VAX161 [STF2.HA5 H5N1]
Sponsor	VaxInnate Corporation
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VAX161 [STF2.HA5 H5N1] CI brief — competitive landscape report
VAX161 [STF2.HA5 H5N1] updates RSS · CI watch RSS
VaxInnate Corporation portfolio CI